Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cutibacterium acnes phylotype IA1 is the principal subgroup of this common, Gram-positive commensal skin bacterium. It is defined by genetic, proteomic, and phenotypic markers and is most strongly associated with the development and severity of acne vulgaris[2][3][4]. Phylotype IA1 exhibits distinct surface antigens, protein expression patterns, and inflammatory potential compared to other *C. acnes* phylotypes[2][3]. It is not a target in the molecular or pharmaceutical sense, but its identification can inform disease correlations and epidemiological studies[1][4]. The IA1 phylotype is routinely detected and distinguished via molecular methods (e.g., MLST, MALDI-MS) and is used in clinical microbiology for understanding strain-specific roles in skin health and disease[1][2][3][4].
Inhibition of bacterial protein synthesis (for macrolides and lincosamides)\nInhibition of bacterial DNA gyrase/topoisomerase (for fluoroquinolones)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cutibacterium acnes phylotype IA1.